The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1662
ISSUE 1662
October 31, 2022
Issue 1662
- Two Vonoprazan Combinations (Voquezna) for H. pylori
- Two New Oral Testosterone Products for Hypogonadism
- Phosphodiesterase-5 Inhibitors for Alzheimer's Disease?
- In Brief: OTC Azelastine Nasal Spray 0.15% (Astepro Allergy) for Allergic Rhinitis
- COVID-19 Update: Novavax Vaccine Authorized for Booster Immunization (online only)
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Two Vonoprazan Combinations (Voquezna) for H. pylori
October 31, 2022 (Issue: 1662)
The FDA has approved vonoprazan, a potassium-competitive
acid blocker, copackaged with amoxicillin
(Voquezna Dual Pak – Phathom) and with amoxicillin
and clarithromycin (Voquezna Triple Pak) for
treatment of Helicobacter pylori infection in...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.